Drug encapsulated in erythrocyte |
Asparaginase encapsulated in erythrocytes (Eryaspase) |
Eryaspase combined with other anti-cancer drugs |
Eryaspase combined with gemcitabine or carboplatin |
Eryaspase combined with either gemcitabine plus abraxane, or irinotecan-based therapy |
Eryaspase combined with gemcitabine or 5-fluoro-uracil/oxaliplatin/leucovorin (FOLFOX) |
Eryaspase combined with GRASPA |
Purpose |
Treatment |
Treatment |
Treatment |
Treatment |
Cancer type |
Triple negative breast cancer |
Pancreatic adenocarcinoma |
Progressive metastatic pancreatic carcinoma |
Acute lymphoblastic leukemia |
Recruitment status |
Recruiting |
Active, not recruiting |
Completed |
Completed |
Sponsor |
ERYtech Pharma |
ERYtech Pharma |
ERYtech Pharma |
Birgitte Klug Albertsen |
Study-type |
Interventional |
Interventional |
Interventional |
Interventional |
No of participants |
64 |
500 |
141 |
55 |
Allocation |
Randomized |
Randomized |
Randomized |
N/A |
Intervention model |
Parallel assignment |
Parallel assignment |
Parallel assignment |
Single group assignment |
Masking |
Open label |
Open label |
Open label |
Open label |
Phase |
Phase 2/3 |
Phase 3 |
Phase 2 |
Phase 2 |
Start of the study |
June 2019 |
September 2018 |
July 2014 |
August 2017 |
Completion of the study |
October 2020 |
October 2021 |
November 2017 |
October 2020 |